Psoriasis in children, clinical and therapeutic conduct

Abstract

Background. Child psoriasis is a continuing, immune system disorder of the skin with distinct challenges Results. ing from distinctions in the biology of the skin, the immune system, maturity, and psychosocial effects. Care is required to be age-related, safe, and multidisciplinary to effectively treat and improve quality. Objective(s). Explore pediatric psoriasis treatments, addressing developmental, immune, and psychological factors, with therapies tailored for age, disease severity, and both shortand long-term safety. Materials and methods. This review gathers up-to-date evidence of pediatric treatment of psoriasis from clinical guidelines and research. It compares topical drugs, phototherapy, systemic therapy, and biologic therapy focusing on safety, efficacy, and psychosocial considerations to support comprehensive, interdisciplinary care of children. Results. Topical therapy with corticosteroids, vitamin D analogs, and calcineurin inhibitors are first-line therapy of mild-to-moderate pediatric psoriasis and are tolerable. Phototherapy with narrowband UVB is beneficial in refractory cases but comes with safety and logistical concerns. Systemic drugs (e.g., methotrexate, cyclosporine) are attempted in severe disease but have organ-related toxicities. Biologics are promising in resistant cases and require long-term follow-through. Holistic management involves psychosocial management with family education and interdisciplinary approach. Conclusion(s). Treatment for psoriasis in children cannot be limited to the management of physical symptoms. Individualization of therapy according to the child's developmental requirements, taking a safety approach towards years of planned therapy and psychosocial support remain the keys to optimizing the outcome.